Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReabold Resources Regulatory News (RBD)

Share Price Information for Reabold Resources (RBD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.0725
Bid: 0.07
Ask: 0.075
Change: 0.005 (7.41%)
Spread: 0.005 (7.143%)
Open: 0.0675
High: 0.0775
Low: 0.0675
Prev. Close: 0.0675
RBD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Gain

14 Feb 2006 07:01

Adventis Group PLC14 February 2006 For release 07.00am 14 February 2006 Adventis Group plc Contract Gain Adventis, the specialist multimedia marketing and advertising agency, announcesthat Affiniti (UK) Ltd, its Bucks-based healthcare agency has been awarded theZanidip account following a three-way pitch. The contract, for an undisclosedamount, is now live. Zanidip (lercanidipine), a highly effective calcium blocker used by GP's tolower blood pressure in the treatment of hyper tension, was originally licensedout but the Italian multi-national pharmaceutical group Recordati S.p.A. has nowopened a UK marketing office and will henceforward market the drug itself. Highblood pressure is a problem most common in the elderly, related to poor controlof the working of the heart, and for kidney and liver diseases. Although Affiniti has been involved before in marketing the Zanidip brand,Recordati were looking for a completely fresh approach to move the productforward. Martin Symons, Recordati's UK General Manager, commented: "It was by no means aforegone conclusion for Affiniti - they had to perform on an even playing fieldagainst good competitors, but they came through very strongly. We look forwardto working with them to develop a strong campaign that will move Zanidip to itsrightful position in the marketplace." Affiniti has also won three other pitches against major league competition: - A major product launch for MabThera in severe rheumatoid arthritis for Roche - A major new European campaign in glaucoma for Allergan's Lumigan - A new campaign for Periostat, a dental root treatment for Alliance Said Affiniti's Managing Director, Stuart Tennant: "Across all these recentpitches we have been up against some of the UK's leading healthcare agencieswith big creative reputations - so we know we can compete at the top level. Weare continuing to build our team, our clients' brands - and a strong reputationof our own." - ENDS - Editor's Notes Adventis Group plc is an AIM listed, full service marketing and advertisingagency, providing services to the property, healthcare and financial servicesindustries. Through its six operating companies the company provides a complete range ofcommunication services, including corporate identity programmes, advertisingcampaigns, media planning & buying, literature, public relation, packaging,exhibitions, research and planning, interiors, signage and digital media. Adventis employs over 80 staff in London and the South East. www.adventis.co.uk Recordati is a European pharmaceutical group mainly dedicated to the research,development, manufacturing and marketing of pharmaceuticals. Headquartered inMilan, it has operations in France, Germany, Greece, Ireland, Italy, Spain,Switzerland, the United Kingdom and the United States. Recordati has been listedon the Italian Stock Exchange since 1984. www.recordati.com Enquiries: Affiniti (UK) LtdStuart Tennant, Managing Director 01494 775 213 Adventis Group plc Charles Phillpot, Chief Executive Officer 020 7034 4750 Seymour PierceJohn Depasquale 020 7107 8000 Binns & Co PR Ltd 020 7786 9600Peter Binns / 07768 392 582Annie Evangeli 07778 507 162 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Nov 20226:22 pmRNSResponse to Presentation from Requisitioners
2nd Nov 20227:00 amRNSInvestor Presentation
1st Nov 20221:15 pmRNSCompletion of the Sale of Corallian to Shell
31st Oct 20229:08 amRNSPosting of Circular and Notice of Requisitioned GM
31st Oct 20227:00 amRNSPosting of Circular and Notice of Requisitioned GM
20th Oct 20227:00 amRNSRequisition of General Meeting
17th Oct 20221:00 pmRNSPurported Requisition of General Meeting
5th Oct 20223:30 pmRNSSPA for Sale of Corallian to Shell for £32 million
30th Sep 20227:00 amRNSUnaudited HY Results for 6 months ended 30/06/22
29th Sep 20227:02 amRNSPublication of PEDL183 CPR by RPS Energy
28th Sep 20227:00 amRNSConditional Acquisition of Simwell Resources
23rd Sep 20227:00 amRNSWest Newton Community Update on Planned Activity
23rd Sep 20227:00 amRNSWest Newton Community Update on Planned Activity
15th Sep 20227:00 amRNSAcquisition of North Sea Assets from Corallian
14th Sep 20227:00 amRNSAgreed Terms of Conditional Sale of Corallian
9th Sep 20224:40 pmRNSSecond Price Monitoring Extn
9th Sep 20224:35 pmRNSPrice Monitoring Extension
9th Sep 20227:00 amRNSResponse to Governmental Energy Plan
1st Sep 20227:00 amRNSUpdate on Corallian and acquisition of licences
14th Jul 20221:56 pmRNSHolding(s) in Company
1st Jul 20227:00 amRNSBoard Change
29th Jun 20224:31 pmRNSResults of Annual General Meeting
23rd Jun 20227:00 amRNSInvestor Presentation
21st Jun 20227:00 amRNSWest Newton Conceptual Development Plan
7th Jun 202211:53 amRNSNotice of AGM – correction of typographical error
1st Jun 202210:06 amRNSNotice of Annual General Meeting
27th May 20227:00 amRNSFull Year Results for the year ended 31 Dec 2021
26th May 20227:00 amRNSCompletion of Equity Exchange Agreement
24th May 20227:00 amRNSReabold North Sea – Presentation on New Licences
23rd May 20227:00 amRNSShareholder Approval Received for Equity Exchange
13th May 20227:00 amRNSAppointment of Chief Financial Officer
4th May 20227:00 amRNSOffer for Corallian and acquisition of licences
3rd May 20227:00 amRNSUpdate on Equity Exchange with Daybreak Oil & Gas
17th Mar 202212:21 pmRNSPlanning Application Approval for Next Phase
25th Feb 20227:00 amRNSInvestor Presentation
25th Feb 20227:00 amRNSUpdate on Equity Exchange with Daybreak Oil & Gas
24th Feb 20224:42 pmRNSSecond Price Monitoring Extn
24th Feb 20224:37 pmRNSPrice Monitoring Extension
17th Feb 202212:38 pmRNSAmendment of Existing Option Terms
25th Jan 20229:05 amRNSSecond Price Monitoring Extn
25th Jan 20229:00 amRNSPrice Monitoring Extension
17th Jan 20224:41 pmRNSSecond Price Monitoring Extn
17th Jan 20224:35 pmRNSPrice Monitoring Extension
17th Jan 20227:00 amRNSWest Newton Flow Rate Update
23rd Dec 20217:00 amRNSVictory – Submission of Draft FDP
2nd Dec 20212:00 pmRNSPrice Monitoring Extension
26th Nov 20217:00 amRNSWest Newton – Rathlin’s Update to Residents
22nd Oct 20217:00 amRNSDirectors’ Dealings
21st Oct 20217:00 amRNSCreation of Enhanced California E&P Company
20th Oct 202111:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.